Table 1 Patient characteristics
CW irradiation | CW + SR irradiation | |||||
|---|---|---|---|---|---|---|
42.5Gy/16F (n = 33) | 36.5Gy/10F (n = 44) | p | 42.5Gy/16F (n = 39) | 36.5Gy/10F (n = 41) | p | |
Age | 0.188 | 0.666 | ||||
< 50 years | 13 (39.4%) | 24 (54.5%) | 20 (51.3%) | 23 (56.1%) | ||
≥ 50 years | 20 (60.6%) | 20 (45.5%) | 19 (48.7%) | 18 (43.9%) | ||
TNM stage (AJCC 7.0)a | 0.322# | 0.224# | ||||
IIa | 20 (60.6%) | 22 (50.0%) | 2 (5.1%) | 0 | ||
IIb | 13 (39.4%) | 21 (47.7%) | 2 (5.1%) | 0 | ||
IIIa | 0 | 1 (2.3%) | 25 (64.1%) | 28 (68.3%) | ||
IIIc | 0 | 0 | 10 (25.7%) | 13 (31.7%) | ||
Histological grade | 0.675# | 0.955# | ||||
I | 1 (3.1%) | 2 (4.5%) | 1 (2.6%) | 1 (2.4%) | ||
II | 21 (63.6%) | 29 (65.9%) | 23 (58.9%) | 24 (58.5%) | ||
III | 11 (33.3%) | 13 (29.6%) | 15 (38.5%) | 16 (39.1%) | ||
Laterality | 1.000 | 0.621 | ||||
Left | 18 (54.5%) | 24 (54.5%) | 24 (61.5%) | 23 (56.1%) | ||
Right | 15 (45.5%) | 20 (45.5%) | 15 (38.5%) | 18 (43.9%) | ||
ER-positive | 24 (63.9%) | 28 (63.6%) | 0.399 | 22 (57.9%) | 30 (73.2%) | 0.116 |
PR-positive | 23 (69.7%) | 27 (61.4%) | 0.448 | 21 (53.8%) | 28 (68.3%) | 0.365 |
HER2-positive | 6 (18.2%) | 10 (22.7%) | 0.627 | 8 (21.1%) | 10 (24.4%) | 0.678 |
ER/PR/HER2-negative | 5 (15.2%) | 11 (25.0%) | 0.292 | 10 (26.3%) | 4 (9.8%) | 0.062 |
LVSI-positive | 5 (15.2%) | 6 (13.6%) | 1.000# | 7 (18.4%) | 10 (24.4%) | 0.481 |
Chemotherapy | 32 (97.0%) | 44 (100%) | 0.429# | 39 (100%) | 41 (100%) | – |
Neoadjuvant CT | 0 | 0 | – | 10 (25.6%) | 8 (19.5%) | 0.512 |
Adjuvant CT | 32 (97.0%) | 44 (100%) | 0.429# | 29 (74.4%) | 33 (80.5%) | 0.512 |
Hormonotherapy | 27 (81.8%) | 29 (65.9%) | 0.121 | 24 (61.5%) | 30 (73.2%) | 0.209 |
Trastuzumab treatment | 6 (18.2%) | 10 (22.7%) | 0.627 | 8 (21.1%) | 10 (24.4%) | 0.678 |